Date: Tuesday, 23 February 2016
Time: 17.30 – 20.00
Address: MedImmune/AstraZeneca, Milstein Building, Granta Park, Cambridge, CB21 6GH
Registration closes on Tuesday, 16 February.
Dr. Susan Galbraith, Vice President, Head of Oncology iMed, AstraZeneca, Cambridge – Tagrisso – the story of the preclinical and clinical development
Dr. Bon-Kyoung Koo, Group Leader, WT-MRC Cambridge Stem Cell Institute, University of Cambridge – Organoids and CRISPR/Cas for autologous cell therapy
Dr. Daniel O’Neill, Senior Research Scientist, Discovery Sciences, AstraZeneca, Cambridge – Generation of novel EGFR C797S cellular models through CRISPR/Cas9-driven precise genome engineering for use in drug discovery
A scientific forum open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations.
The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists at these organisations in order to improve opportunities for biotechnology research and development.
Launched in 2015, CamNTF hosts early-evening meetings open to all scientists interested in research into new therapeutics. These rotate around different organisations located in the Cambridge biotech cluster. Each two-hour session will begin with short scientific presentations and will be followed by networking and snacks (6pm-8pm). Attendance is free but all attendees must register in advance. Places are limited and early registration will be important to avoid disappointment! Registration closes one week prior to the meeting.
Professor Sir Tom Blundell (University of Cambridge, Sir William Dunn Professor of Biochemistry),
Professor Patrick Maxwell (University of Cambridge, Regius Professor of Physic, Director Cambridge University Health Partners),
Professor Michael Wakelam (Babraham Institute, Director),
Professor Ewan Birney (EMBL-EBI, Associate Director),
Dr Mene Pangalos (AstraZeneca, R&D Director),
Professor Ian Wilkinson (University of Cambridge, Professor of Therapeutics; Director of CUHP’s Office for Translational Research).